home / stock / celu / celu news

CELU News and Press, Celularity Inc.

Stock Information
Company Name: Celularity Inc.
Stock Symbol: CELU
Market: NASDAQ
Website: celularity.com
Menu
CELU CELU Quote CELU Short CELU News CELU Articles CELU Message Board
Get CELU Alerts

News, Short Squeeze, Breakout and More Instantly...
CELU - NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 mil...
CELU - Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are pote...

CELU - Celularity secures strategic license deal worth up to $35M for biomaterials portfolio

2026-03-10 08:45:12 ET More on Celularity Seeking Alpha’s Quant Rating on Celularity Financial information for Celularity Read the full article on Seeking Alpha For further details see: Celularity secures strategic license deal worth up to $35M for...

CELU - NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance...
CELU - Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity Organizational realignment reduces operating expenses and sharpens focus on longevity therapeuti...

CELU - Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unu...

CELU - Organogenesis, MiMedx among decliners as Medicare to pull skin substitute LCDs

2025-12-26 10:41:52 ET More on Organogenesis Holdings, MiMedx Group Organogenesis: High-Tech Skin Substitute Company On Sale Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript MiMedx: Breakout Setup Into A Policy Overhaul Organogenesis starts...
CELU - Organogenesis drops as Medicare to pull skin substitute LCDs (update)

2025-12-26 11:09:21 ET More on Organogenesis Holdings, MiMedx Group Organogenesis: High-Tech Skin Substitute Company On Sale Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript MiMedx: Breakout Setup Into A Policy Overhaul Organogenesis starts...

CELU - Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comments by Robert J. Hariri, M.D., Ph.D., CEO and Chairman, on the Cent...

CELU - Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Phi...
Next 10